Expression of mdrl, mrp, topoisomerase IIα/β, and cyclin A in primary or relapsed states of acute lymphoblastic leukaemias
Expression of mdrl, mrp, topoisomerase IIα/β, and cyclin A in primary or relapsed states of acute lymphoblastic leukaemias
复制标题
mdrl、mrp、拓扑异构酶 IIα/β 和细胞周期蛋白 A 在急性淋巴细胞白血病原发或复发状态中的表达
DOI：
--
复制
发表时间：
1995
期刊：
影响因子：
--
通讯作者：
V. Gekeler
中科院分区：
文献类型：
--
作者：
J. Beck;R. Handgretinger;R. Dopfer;T. Klingebiel;D. Niethammer;V. Gekeler
Summary. In a series of 60 ALL samples drawn during different stages of the disease we used a cDNA‐PCR approach to analyse the relative mRNA levels of the MDR‐associated genes encoding mdrl/P‐glycoprotein, mrp, and the topoisomerase II isozymes α and β. Expression analysis of the cyclin A gene was included to examine cellular proliferation activity. The expression of gapdh served as an internal standard. Calculating the mean values we found: (i) a distinctly lower mdrl gene expression in primary ALL and first relapses compared to bone marrow from healthy donors, (ii) no change in mdrl and mrp, but a decreased topoisomerase IIα gene expression in first relapses of ALL compared to the primary leukaemia, and (iii) increased mdrl and mrp levels combined to decreased topoisomerase IIα levels in recurrent relapses of ALL showing significant correlations (mdrl/mrp: rs=+0.6833, P<0.05: mdrl/topollα: rs− 0.6727, P < 0.05). The expression of the topoisomerase IIá gene was correlated to that of cyclin A, indicating a link of its expression to cellular proliferation. Our findings suggest that a multifactorial MDR including mrp appears particularly in recurrent relapses of ALL. which often do not respond to chemotherapy. Nonetheless, some individual samples showed gene expression levels very different from the mean values calculated for a particular state of the leukaemia, indicating the need of an individual expression analysis of MDR‐associated genes.
影响因子：
20.3
作者：
D. Drach;Shourong Zhao;J. Drach;R. Mahadevia;Claus Gattringer;Heinz Huber;M. Andreeff
通讯作者：
D. Drach;Shourong Zhao;J. Drach;R. Mahadevia;Claus Gattringer;Heinz Huber;M. Andreeff
对 VM-26 和 m-AMSA 耐药的人白血病细胞中核基质 DNA 拓扑异构酶 II 减少。
影响因子：
2.9
作者：
Fernandes,DJ;Danks,MK;Beck,WT
通讯作者：
Beck,WT
成人急性白血病的多药耐药性（mdr1）基因表达：与治疗结果和体外药物敏感性的相关性。
影响因子：
20.3
作者：
Marie,JP;Zittoun,R;Sikic,BI
通讯作者：
Sikic,BI